Revvity lowers profit forecast due to reduced demand for diagnostics in China, shares drop 10%. Sales in China declined by double digits in Q2. Changes in hospital lab reimbursement policy affecting revenue. Abbott also impacted, with $700 million revenue loss in 2025. Physicians shifting to simpler diagnostics, affecting Revvity’s business.

Revvity expects adjusted profit per share for 2025 to be lower than previously projected. Despite challenges, Q2 results in line with industry peers. Life sciences product sales exceed estimates. Full-year revenue forecast slightly raised due to weaker U.S. dollar. Larger peers Danaher and Thermo Fisher Scientific see improving conditions in China’s pharma sector.

Read more at Yahoo Finance: Revvity trims 2025 profit forecast as China policy changes hit diagnostics demand